Open Studies

(Updated October 2020)

ACCRF has compiled a list of clinical trials for ACC patients with progressive disease to consider. This website is updated periodically, but may not list all the pertinent and available trials. Patients may search on their own for recruiting ACC clinical trials on the ClinicalTrials.gov website.

The clinical trials are broken down into three categories.

  • The first table lists studies that are recruiting any and all ACC patients (usually phase II clinical trials).
  • The second table lists studies appropriate for ACC patients whose tumors have been profiled and found to have activating alterations in NOTCH genes (either phase I or II clinical trials).
  • The third table includes clinical trials that incorporate tumor profiling prior to selecting a drug (“basket studies”).

In all cases, patients should consult with their physicians to discuss the appropriate course of action.

Not all clinical trials have similarly strong scientific rationales for why the drugs should be effective in ACC. The most promising studies will involve drugs that (1) target the known mechanisms of action that drive ACC progression, (2) demonstrate activity in preclinical models of ACC, and (3) have reports of clinical benefit in an ACC patient from a case study or Phase I clinical trial. To assist patients in appraising each clinical trial, we indicate whether the evidence supporting the scientific rationale is strong, solid or fair. This assessment is based on the underlying scientific rationale, and does not mean that a particular trial is better or worse for any given patient, and should be considered along with his or her physician.

The table below lists clinical trials that currently are recruiting ACC patients in particular or salivary gland cancer patients. Unless otherwise noted, these studies are for only ACC patients with recurrent or metastatic disease. Links are provided to descriptions of the drugs as well as the www.ClinicalTrials.gov summary of each study.

Clinical Trials for All ACC Patients
Compound TargetsSponsor Locations Scientific Rationale Info Link Contact
Lenvatinib and Pembrolizumab VEGFR and PD-1 Immunotherapy Memorial Sloan-Kettering New York, NY, USA Very Strong View Alan Ho, MD, PhD
646-888-4235
hoa@mskcc.org
GSK3326595 (for patients without prior systemic drugs) PRMT5 GSK Multiple sites in Canada, France, Netherlands and USA Strong View US: 877-379-3718 GSKClinicalSupportHD@gsk.com
EU: +44(0)20 89904466 GSKClinicalSupportHD@gsk.com
PRT-543 PRMT5 Prelude Therapeutics Houston, TX, USA Strong View Renata Ferrarotto, MD
1-713-792-6363
MYB vaccine and Tislelizumab MYB & PD-1 Immunothera Peter MacCallum Cancer Centre Melbourne, Australia Strong View Jayesh Desai
+61 38559 7810
jayesh.desai@petermac.org
Lutetium-177-PSMA / Radioligand Therapy PSMA Radboud University Nijmegen, Netherlands Strong View Carla ML van Herpen, MD, PhD
+31243613457
Carla.vanHerpen@radboudumc.nl
Lutetium-177-PSMA / Radioligand Therapy PSMA Peking Union Medical College Hospital Beijing, China Strong View Zhaohui Zhu, MD
86-13611093752
13611093752@163.com
ATRA Combinations MYB Shanghai Ninth People's Hospital Shanghai, China Strong View Guopei Zhu, MD
021-23271699 ext 5665
antica@gmail.com
Pembrolizumab and Docetaxel PD-1 Immunotherapy University of Chicago Chicago, IL, USA Solid View Alexander Pearson, MD, PhD
apearson5@medicine.bsd.uchicago.edu
Chidamide and Cisplatin HDAC Fudan University Shanghai, China Solid View Kai Xue, MD
021-64175590
xuekaishanghai@126.com
Chidamide HDAC Chinese Academy of Medical Sciences Beijing, China Fair View Mei Dong
+86-10-87788130
Dongmei030224@163.com
Nivolumab and Ipilimumab and Radiation PD-1 and CTLA-4 Immunotherapy University of Washington Seattle, WA, USA Fair View Susan Masterson
1-206-606-7445
smasters@seattlecca.org
Stereotactic Body Radiation Therapy (for patients with up to 3 metastases) Oligometastases Dana Farber Boston, MA, USA Solid View Jonathan D Schoenfeld, MD, MPH
617-632-5296
jonathan_schoenfeld@dfci.harvard.edu
Glenn J Hanna, MD
617-632-3090
glenn_hanna@dfci.harvard.edu
Axitinib and Avelumab VEGFR, PDGFR, KIT and PD-L1 Immunotherapy MD Anderson Houston, TX, USA Very Strong View Renata Ferrarotto, MD
1-713-792-6363

Approximately 25% of metastatic ACC patients have tumors with activating alterations in the NOTCH pathway (primarily in the NOTCH1 gene). These tumors behave more aggressively. Patients for whom tumor profiling has identified a NOTCH pathway alteration may wish to discuss the following studies with their physicians:

Clinical Trials for ACC Patients with Activating NOTCH Alterations
Compound TargetsSponsor Locations Scientific Rationale Info Link Contact
AL101 NOTCH Ayala Pharmaceutical Calgary, Alberta, Canada
Hamilton, Ontario, Canada
London, Ontario, Canada
Villejuif, France
Petah Tikva, Israel
Nijmegen, Netherlands
Manchester, UK
Aurora, CO, USA
Baltimore, MD, USA
Boston, MA, USA
Houston, TX, USA
Los Angeles, CA, USA
Miami, FL, USA
New York, NY, USA
Rochester, MN, USA
Tampa, FL, USA
Seattle, WA, USA
Strong View Accuracy@ayalapharma.com
CB-103 NOTCH Cellestia Pharmaceuticals Barcelona, Spain
Madrid, Spain
Bellinzona, Switzerland
Saint Gallen, Switzerland
Houston, TX, USA
Santa Monica, CA, USA
Strong View Florian Vogl, MD, PhD
+41 61 6332957
florian.vogl@cellestia.com

Historically, clinical trials involved only one or two treatments. Some newer trials are incorporating tumor profiling to direct patients to many more potential treatments within the same study. These “basket trials” try to match targeted drugs to genomic alterations in each patient’s particular tumor. Some of these trials profile the patient’s tumor as party of the study (NCI-MATCH) while others will suggest treatment decisions based on existing tumor profiling reports (ASCO TAPUR). The clinical trials listed below are not specifically for ACC patients, but may be worth considering in consultation with a knowledgeable physician.

Studies for ACC Patients with Unresectable (Inoperable), Locally-Advanced Tumors
Compound Modality Sponsor Locations Info Link Contact
CV8102 (for superficial and readily-accessible head & neck tumors) Injection of TLR7/8 agonist CureVac Multiple sites in Germany View Thomas Eigentler, Prof. Dr.
thomas.eigentler@med.uni-tuebingen.de
Apatinib and Proton Radiation (for inoperable or residual ACC) Shanghai Proton and Heavy Ion Center Shanghai, China View Lin Kong, MD lin.kong@sphic.org.cn
Jiyi Hu, MD jiyi.hu@sphic.org.cn
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Radiation Massachusetts General Hospital Boston, MA, USA View Annie W Chan, MD
617-724-1159
awchan@partners.org
Carbon Ion Only Irradiation vs Boost (ACCO) Radiation Heidelberg University Heidelberg, Germany View Klaus Herfarth, Prof. Dr.
+49 6221 568201
klausherfarth@med.uni-heidelberg.de
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors (ETOILE) Radiation Hospices Civils de Lyon Multiple sites in France View Pascal Pommier, MD
(0)4 78 78 51 66 ext +33
pascal.pommier@lyon.unicancer.fr